RE
IMUC

RBC Europe’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History

RBC Europe’s Portfolio IMUC Stock Details IMUC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-2
Closed – – 1176
2018
Q3 		$0 Hold
2
– – ﹤0.01% 1194
2018
Q2 		$1 Hold
2
– – ﹤0.01% 1145
2018
Q1 		$1 Hold
2
– – ﹤0.01% 1126
2017
Q4 		$1 Hold
2
– – ﹤0.01% 1137
2017
Q3 		$1 Buy
+2
New +$1 ﹤0.01% 1138

Other funds holding IMUC

WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

RBC Europe's IMUC Position: Q4 2018 in Review

RBC Europe sold out of ImmunoCellular Therapeutics, Ltd. (IMUC) in Q4 2018, closing a stake of 2 shares.

RBC Europe first reported a position in IMUC in Q3 2017 and held it in 5 quarters. The position peaked at $1 in Q2 2018. 3 funds tracked by Wall St. Rank hold IMUC as of Q4 2018.

  • RBC Europe reported no remaining ImmunoCellular Therapeutics, Ltd. position as of Q4 2018 after selling out during the quarter.
  • RBC Europe sold 2 ImmunoCellular Therapeutics, Ltd. shares in Q4 2018.
  • RBC Europe first reported a position in ImmunoCellular Therapeutics, Ltd. in Q3 2017 and held it in 5 quarters.
  • RBC Europe's ImmunoCellular Therapeutics, Ltd. position peaked at $1 in Q2 2018.
  • 3 funds tracked by Wall St. Rank held ImmunoCellular Therapeutics, Ltd. as of Q4 2018.

Based on RBC Europe's 13F filing for Q4 2018, filed 9 Nov 2023.